Chris Kruger has joined Zosano Pharma as chief business officer.
He joins the US-based biopharma from Ardea Biosciences, where he served as senior VP and chief business officer.
During his time at Ardea, Krueger completed a $407m global partnership with Bayer HealthCare.
In his new role, he will be responsible for business development, legal, and investor relations activities of Zosano as it prepares to expand its efforts in developing drug’s utilising its novel drug delivery system.
Additional previous roles Krueger has held include senior executive positions at Protemix, Xencor, X–Ceptor Therapeutics and Aurora Biosciences.
His experience includes a broad range of transactions, including licensing, strategic alliances, mergers and acquisitions and equity and debt financings.
“It’s exciting for me to join the Zosano team as the company enters its next stage of corporate growth,” said Krueger.
“With its novel transdermal drug delivery system, Zosano is poised to develop therapeutic products through its own efforts and through strategic collaborations.”